In the EMBER-3 study, estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer patients were randomized to receive imlunestrant alone, ...
Eli Lilly (LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant, an investigational, oral selective estrogen receptor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback